Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $8.2B covered $1.9B of dividends and buybacks. Cash fell by $4.1B. Lines the picture does not name came to −$3.9B. What is a cash flow statement?
- Free cash flow
- $8.2B 72.1% of operating cash flow
- Returned to shareholders
- $1.9B 23.3% of free cash flow
- Debt, net
- −$5.3B repaid
- Change in cash
- −$4.1B over the period
| Operating cash flow | 11.4 |
|---|---|
| Capital expenditures | −3.2 |
| Free cash flow | 8.2 |
| Acquisitions, net | −0.9 |
| Into investments, net | −0.3 |
| Dividends | −1.5 |
| Buybacks, net | −0.4 |
| Debt repaid, net | −5.3 |
| Other | −3.9 |
| Change in cash | −4.1 |
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $3.2B | $5.3B | $10.7B | $11.4B |
| Capex | −$2.5B | −$2.3B | −$2.9B | −$3.2B |
| Free cash flow | $678M | $3.0B | $7.8B | $8.2B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more quarters Free account |
6,638.00 | 7,396.00 | 7,095.00 | 6,451.00 |
Depreciation & Amortization |
586.00 | 509.00 | 534.00 | 545.00 | |
Non Cash Items (Other) |
4,776.00 | (908.00) | 4,197.00 | 1,817.00 | |
Change in other assets and liabilities |
(7,291.00) | (1,664.00) | (1,136.00) | 2,584.00 | |
Operating Cash Flow |
3,225.00 | 5,333.00 | 10,690.00 | 11,397.00 | |
Capital expenditures |
(2,547.00) | (2,326.00) | (2,933.00) | (3,178.00) | |
Net Aquisitions |
— | (1,058.00) | (8,747.00) | (887.00) | |
Short Term Investments Change (Net) |
— | — | (604.00) | — | |
Long-Term Investments Change (Net) |
837.00 | (297.00) | — | — | |
Other investing activities |
(1,642.00) | (235.00) | (3,409.00) | (3,976.00) | |
Investing cash flow |
(2,803.00) | (3,916.00) | (15,396.00) | (8,299.00) | |
Repayment/Issuance of Debt (Net) |
0.00 | 1,025.00 | 11,577.00 | (5,284.00) | |
Equity Repurchase (Common, Net) |
(1,508.00) | (2,356.00) | (1,601.00) | (377.00) | |
Dividends Paid (Total) |
(1,345.00) | (1,548.00) | (1,546.00) | (1,541.00) | |
Other financial activities |
(26.00) | (591.00) | (4.00) | (17.00) | |
Financing cash flow |
(2,879.00) | (3,470.00) | 8,426.00 | (7,219.00) | |
Exchange Rate Adjustment |
(67.00) | 67.00 | (52.00) | 56.00 | |
Change in Cash |
(2,524.00) | (1,986.00) | 3,668.00 | (4,065.00) | |
Beginning Cash |
0.00 | 7,268.00 | 0.00 | 0.00 | |
Ending Cash |
(2,524.00) | 5,282.00 | 3,668.00 | (4,065.00) | |
Stock Based Compensation |
136.00 | 161.00 | 201.00 | 200.00 | |
Dividends Paid (Common) |
(1,345.00) | (1,548.00) | (1,546.00) | (1,541.00) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(8,775.00) | (1,664.00) | (1,136.00) | 2,584.00 | |
Investments Change (Net) |
837.00 | (297.00) | (307.00) | (258.00) | |
Issuance/Purchase of Shares |
(1,508.00) | (2,356.00) | (1,601.00) | (377.00) |